05th March 2022 | Pharma Updates
Lupin receives approval from the USFDA to commercialise a generic product.
The US Food and Drug Administration (FDA) has given the company permission to commercialise the generic version of Bausch Health Americas’ Jublia topical solution used to treat fungal toenail infections.
Skye Air Mobility and Redcliffe Labs have started BVLOS trials
The first set of BVLOS trials, demonstrating a speedier supply chain for sample delivery, resulting in faster diagnostic findings, was successfully launched in Noida, Greater Noida, and Meerut.
With rapid therapeutic development, the FDA continues to prioritise rare diseases
The FDA’s Center for Treatment Evaluation and Research (CDER) is working to improve drug development for rare diseases by exchanging data with the Critical Path Institute and building the Rare Disease Cures Accelerator-Data and Analytics Platform.
LumiThera, a developer of dry AMD treatments, has acquired Diopsys, a retinal diagnostics company
LumiThera, a company that develops lightbased treatments for eye illnesses like agerelated macular degeneration (AMD), has acquired the maker of a diagnostic device that it thinks will complement its efforts to track patients who are losing their vision.
Spina Bifida is a growing concern on World Birth Defects Day
The Latin phrase “Spina Bifida” directly translates to “Split Spine.” Every year, around 8 million newborns are born with significant birth abnormalities, which can be structural, functional, or metabolic in nature.
Covaxin, an Ocugen COVID vaccine, has been denied a paediatric EUA by the FDA
Ocugen intends to continue working with the US Food and Drug Administration to assess the procedure for obtaining an EUA for Covaxin use in children.
Hutchmed names a new CEO, with a veteran CSO taking the reins ahead of the company's first US medicine launch
Chrisian Hogg, Hutchmed’s first employee and longtime CEO, is resigning after a 15-year stint, just as the Chinese business prepares to enter the US market.
Molnupiravir, an antiviral medication, is recommended by the WHO for non-severe COVID-19 patients
The proposal is based on new data from six randomised controlled studies involving 4,796 individuals, according to the WHO Guideline Development Group of worldwide specialists. This is the most comprehensive database on this medicine to date.
In a large UK trial, an arthritis medicine was found to minimise the chance of COVID death
As part of the so-called RECOVERY experiment, over 8,000 patients were given baricitinib in addition to usual care, at random, or usual care alone, according to investigators from the University of Oxford.
Pfizer and Moderna are well-positioned to take mRNA forward in the future
The success of the COVID-19 vaccines, which both firms produced or co-developed utilising mRNA technology, has fattened Moderna and Pfizer. In 2022, the top vaccination companies are expected to nearly treble their sales, indicating that mRNA has a promising future.
